When tested in vivo, however, neratinib did not affect tumor growth of PDX-BRS18 (Fig. 2C,F), even though drug treatment decreased both total and phosphorylated HER2 (Fig. 2I). This evidence concerns the gene ERBB2 and neoplasm.